{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-25-001763","form_type":"8-K","ticker":"SLXN","cik":"0002022416","company_name":"Silexion Therapeutics Corp","filed_at":"2025-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.696828+00:00","generated_at":"2026-05-21T19:02:57.516103+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Silexion Therapeutics Q1 2025 net loss $1.7M; cash $6.2M; SIL204 shows ~70-80% tumor reduction","bullets":["Net loss $1.7M in Q1 2025 vs $1.4M in Q1 2024; total operating expenses $1.7M (R&D $0.6M, G&A $1.1M).","Cash and cash equivalents $6.2M as of Mar 31, 2025, up from $1.2M in Dec 31, 2024, after ~$9.2M gross raised.","SIL204 orthotopic data: ~70% tumor cell reduction in AsPC-1 (G12D) and ~80% in BxPC-3 by day 28; reduced metastases.","Expanded dual-route (systemic + intratumoral) development strategy for SIL204; clinical trials targeted for H1 2026.","Post-quarter strategic collaboration with Catalent for formulation and clinical manufacturing of SIL204."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-25-001763","json":"https://secwatch.observer/filing/0001178913-25-001763.json","markdown":"https://secwatch.observer/filing/0001178913-25-001763.md","text":"https://secwatch.observer/filing/0001178913-25-001763.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2022416/000117891325001763/0001178913-25-001763-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2022416/000117891325001763/zk2533189.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T19:02:57.516103+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}